Weekly News Round-up – 11/9/20

In the news this week, Oxford University and AstraZeneca have temporarily suspended their joint COVID-19 vaccine trials over safety fears as a subject falls ill. In other news, GSK and Sanofi begin their own COVID trials, and a group of...

3 months ago
Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 11/9/20

In the news this week, Oxford University and AstraZeneca have temporarily suspended their joint COVID-19 vaccine trials over safety fears as a subject falls ill. In other news, GSK and Sanofi begin their own COVID trials, and a group of...

3 months ago

Weekly News Round-Up – 14/8/20

In the news this week, the race for a vaccine begins to near its conclusion as the U.S. and U.K. continue to buy up supplies of promising vaccines, and Moderna comes under criticism for its steep prices that make the...

4 months ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-Up – 14/8/20

In the news this week, the race for a vaccine begins to near its conclusion as the U.S. and U.K. continue to buy up supplies of promising vaccines, and Moderna comes under criticism for its steep prices that make the...

4 months ago

Weekly News Round-up – 7/8/20

In the news this week, vaccine deals are afoot on either side of the Atlantic: both the U.K. and U.S. governments have signed deals with Sanofi and GSK for doses of their COVID-19 vaccine, while the UK has also requested...

4 months ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 7/8/20

In the news this week, vaccine deals are afoot on either side of the Atlantic: both the U.K. and U.S. governments have signed deals with Sanofi and GSK for doses of their COVID-19 vaccine, while the UK has also requested...

4 months ago

Weekly News Round-up – 17/7/20

In the news this week, despite significant alarms recently that GSK’s belantamab mafodotin could endanger patients’ eyes, the multiple myeloma drug has been approved by expert advisers. In other news, Novartis promises to make no profit from 15 of its COVID...

5 months ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 17/7/20

In the news this week, despite significant alarms recently that GSK’s belantamab mafodotin could endanger patients’ eyes, the multiple myeloma drug has been approved by expert advisers. In other news, Novartis promises to make no profit from 15 of its COVID...

5 months ago

Weekly News Round-up – 10/7/20

In the news this week, the Trump Administration has made another deal to acquire all initial doses of a potential COVID-19 drug, in this case Regeneron’s REGN-COV2. This follows their acquisition of the first batches of Gilead’s remdesivir last week....

5 months ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 10/7/20

In the news this week, the Trump Administration has made another deal to acquire all initial doses of a potential COVID-19 drug, in this case Regeneron’s REGN-COV2. This follows their acquisition of the first batches of Gilead’s remdesivir last week....

5 months ago

Weekly News Round-up – 3/7/20

Big news this week, with the U.S. administration buying up remdesivir’s stock for the next three months, ensuring no other country will receive any. In other news, Pfizer and BioNTech’s own covid drug has shown promising results in early trials,...

5 months ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 3/7/20

Big news this week, with the U.S. administration buying up remdesivir’s stock for the next three months, ensuring no other country will receive any. In other news, Pfizer and BioNTech’s own covid drug has shown promising results in early trials,...

5 months ago

Weekly News Round-up – 19/6/20

This week, pharma begins looking beyond the imminent struggle against Covid-19’s initial challenges to the further horizon, and the dreaded second wave. Vaccine demand in a number of countries is rising in preparation of easing lockdowns, while Gilead’s remdesivir starts...

6 months ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 19/6/20

This week, pharma begins looking beyond the imminent struggle against Covid-19’s initial challenges to the further horizon, and the dreaded second wave. Vaccine demand in a number of countries is rising in preparation of easing lockdowns, while Gilead’s remdesivir starts...

6 months ago

Weekly News Round-up – 5/6/20

The race for a COVID-19 vaccine continues, with AstraZeneca set to double potential capacity after a new deal struck with two companies supported by Bill and Melinda Gates. In other news, the WHO is set to restart trials for hydroxychloroquine,...

6 months ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 5/6/20

The race for a COVID-19 vaccine continues, with AstraZeneca set to double potential capacity after a new deal struck with two companies supported by Bill and Melinda Gates. In other news, the WHO is set to restart trials for hydroxychloroquine,...

6 months ago

Weekly News Round-up – 22/5/20

Big news this week, with AstraZeneca potentially ready to produce a Covid-19 vaccine by September this year, and Moderna receiving good news about its early-stage human trials for the same thing. In other news, the Trump administration’s new manufacturing partner...

7 months ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 22/5/20

Big news this week, with AstraZeneca potentially ready to produce a Covid-19 vaccine by September this year, and Moderna receiving good news about its early-stage human trials for the same thing. In other news, the Trump administration’s new manufacturing partner...

7 months ago

Weekly News Round-up – 15/5/20

In the news this week, remdesivir is authorised for emergency use in COVID-19. The drug has still not been proven to increase survival rates, but it will be vital to reduce patient recovery times. In other news, Takeda announces surprise...

7 months ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 15/5/20

In the news this week, remdesivir is authorised for emergency use in COVID-19. The drug has still not been proven to increase survival rates, but it will be vital to reduce patient recovery times. In other news, Takeda announces surprise...

7 months ago